Alerts
Holiday Hours Information

In recognition of the Christmas and New Year’s holidays, some of The University of Kansas Cancer Center’s offices will have modified hours on Wednesday, December 25, and Wednesday, January 1.

Skip Navigation

A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib NSC-763760 and Trametinib NSC-763093 in BRAFV600E/K Mutant Melanoma

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT02196181

Study #:
STUDY00002735

Start Date:
Aug 16, 2015

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT02196181

View Complete Trial Details & Eligibility at ClinicalTrials.gov